Cart
sales@molnova.com
glucosylvitexin
CAS No. 76135-82-5
glucosylvitexin ( —— )
Catalog No. M19085 CAS No. 76135-82-5
Glucosylvitexin inhibits TPO activity.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 69 | In Stock |
|
| 10MG | 97 | In Stock |
|
| 25MG | 161 | In Stock |
|
| 50MG | 239 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Nameglucosylvitexin
-
NoteResearch use only, not for human use.
-
Brief DescriptionGlucosylvitexin inhibits TPO activity.
-
DescriptionGlucosylvitexin inhibits TPO activity.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
RecptorTPO
-
Research AreaMetabolic Disease
-
Indication——
Chemical Information
-
CAS Number76135-82-5
-
Formula Weight610.52
-
Molecular FormulaC27H30O16
-
Purity98%
-
Solubility——
-
SMILESc1(cc(=O)c2c(cc(c(c2o1)C1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO)CO)O)O)c1ccc(cc1)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gaitan E,et al. Antithyroid and goitrogenic effects of millet: role of C-glycosylflavones. J Clin Endocrinol Metab. 1989 Apr;68(4):707-14.
molnova catalog
related products
-
Risperidone mesylate
An antipsychotic agent with serotonin-S2 and dopamine-D2 antagonistic properties.
-
Homoeriodictyol
Homoeriodictyol, a naturally occurring, bitter-masking flavanone, as a promising agent to increase appetite and food intake. The flavanone homoeriodictyol can increase SGLT-1-mediated glucose uptake but decrease serotonin release in differentiated Caco-2 cells.In contrast to other polyphenols, the flavanon Homoeriodictyol promotes glucose uptake by 29.0 ± 3.83% at a concentration of 100 μM.
-
Pergolide mesylate s...
PERGOLIDE MESYLATE is a long-acting dopamine agonist which has been used to treat parkinson disease and hyperprolactinemiabut withdrawn from some markets due to potential for heart valve diseases.
